Primera Bioscience Research Inc. Announces Closing of Previously Announced Acquisition
(Marketwire (Canada) Via Acquire Media NewsEdge) TORONTO, ONTARIO--(Marketwired - June 9, 2014) - Primera Bioscience Research Inc. ("Primera" or the "Company") is pleased to announce that further to its news release of May 20, 2014, it has completed the acquisition of Copenhagen Minerals Inc. ("CMI") in a share purchase transaction (the "Acquisition"). As a result, the Company now owns a 100% interest in the Storo Gold Project, an exploration project located in Greenland. The Company's name will be changed to "Greenland Resources Inc." to reflect this Acquisition.
The Company also announces the appointment of Ruben Shiffman, Jesper Kofoed, and Leonard Asper to the board of directors, the appointment of Mr. Shiffman as Chairman, and Mr. Kofoed as CEO, effective June 5, 2014. Dennis Waddington will continue as Chief Financial Officer and Corporate Secretary.
The Company also announces the resignations of Carolyn J. Rayfield as director and CEO, and of Maria Bruzzese and Christine Davison as directors. Primera thanks Ms. Rayfield, Ms. Bruzzese and Ms. Davison for their contributions to the Company during their respective tenures. We wish them well in their future endeavours.
Pursuant to the acquisition of CMI, the following individuals acquired common shares of the Company ("Shares") at a deemed price of $0.10 per Share: Mr. Shiffman of 80 Richmond St. W., Toronto, Ontario, M5H 2A4, acquired ownership of 6,550,000 Shares; Mr. Asper of 35 Hazelton Ave., 2nd Floor, Toronto, Ontario, M5R 2E3, acquired control over 5,550,000 Shares; and Mr. Kofoed of 80 Richmond St. W., Toronto, Ontario, M5H 2A4, acquired 4,550,000 Shares. None of Messrs. Shiffman, Asper, or Kofoed held shares of the Company prior to the Acquisition. Upon completion of the Acquisition, the respective shareholdings of Messrs. Shiffman, Asper, and Kofoed represent approximately 31.2%, 26.4%, and 21.6% of the outstanding Shares. Each of these Share acquisitions was completed for investment purposes, and none of Messrs. Shiffman, Asper, or Kofoed have any current intention to increase the beneficial ownership of, or control or direction over, securities of the Company. The Company is relying on an exemption from the prospectus requirement set out in section 2.16 of National Instrument 45-106, which relates to distributions in connection with a take-over bid.
ON BEHALF OF THE BOARD OF DIRECTORS
For more information, or to obtain a copy of the applicable securities reports filed in connection with the matters set forth above, please contact Ruben Shiffman.
FOR FURTHER INFORMATION PLEASE CONTACT:
Primera Bioscience Research Inc.
Source: Primera Bioscience Research Inc.
[ Back To TMCnet.com's Homepage ]